1. In Vivo
  2. >>Archive

At AAOS, Should Product Companies Fear Physician Employment?

By some estimates, nearly half of all physicians in certain specialties are no longer independent practitioners, but work within some collaborative arrangement with hospitals as full-time employees. Cardiologists and cardiovascular surgeons are leading the way, but orthopedic surgeons aren't far behind. In a session at this year's American Academy of Orthopedic Surgeons meeting, entitled "Hospitals Buying Surgeon Group Practices: Passing Trend or New Paradigm?," surgeons, hospital executives, and consultants offered their thoughts as to where this trend might lead.

By some estimates, nearly half of all physicians in certain specialties are no longer independent practitioners, but have sold their practices and/or work within some collaborative arrangement with hospitals as full-time employees. Cardiologists and cardiovascular surgeons are leading the way, but orthopedic surgeons aren't far behind.

And, according to the American Academy of Orthopedic Surgeons (AAOS), the trend is accelerating: recent data suggest that over the past couple of years, the number of orthopedic surgeons employed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.